Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about GlycoMimetics, Inc.
GlycoMimetics, Inc. News
GlycoMimetics, Inc. Quantitative Score
About GlycoMimetics, Inc.
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
GlycoMimetics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
GlycoMimetics, Inc. Financials
Table Compare
Compare GLYC metrics with: | |||
|---|---|---|---|
Earnings & Growth | GLYC | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | GLYC | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | GLYC | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | GLYC | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
GlycoMimetics, Inc. Income
GlycoMimetics, Inc. Balance Sheet
GlycoMimetics, Inc. Cash Flow
GlycoMimetics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
GlycoMimetics, Inc. Executives
| Name | Role |
|---|---|
| Harout Semerjian | Chief Executive Officer & President |
| Brian Hahn | Senior Vice President & Chief Financial Officer |
| Bruce Johnson | Senior Vice President & Chief Commercial Officer |
| Chinmaya Rath | Senior Vice President & Chief Business Officer |
| Christian Dinneen-Long | General Counsel & Company Secretary |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Harout Semerjian | Chief Executive Officer & President | Male | 1970 | 1.1M |
| Brian Hahn | Senior Vice President & Chief Financial Officer | Male | 1974 | 728.55K |
| Bruce Johnson | Senior Vice President & Chief Commercial Officer | Male | 1968 | -- |
| Chinmaya Rath | Senior Vice President & Chief Business Officer | Male | 1977 | -- |
| Christian Dinneen-Long | General Counsel & Company Secretary | Male | -- |